Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Kuvan er større end risiciene ved Kuvan til behandling af HPA hos voksne og pædiatriske patienter med PKU og BH4- defekt, som har vist sig at være responsive over for denne behandling.
The Committee for Medicinal Products for Human Use (CHMP) decided that Kuvan’ s benefits are greater than its risks for the treatment of HPA in adult and paediatric patients with PKU and with BH4 deficiency, who have been shown to be responsive to such treatment.